StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $12.34 | $12.08 | -2.11% | 0.1M |
| 05-12 | $12.07 | $11.84 | -1.91% | 0.1M |
| 05-13 | $11.67 | $11.65 | -0.17% | 0.1M |
| 05-14 | $11.55 | $11.85 | +2.60% | 0.1M |
| 05-15 | $11.37 | $11.49 | +1.06% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
| Metric | Q4 2024 2024-12-31 | Q3 2024 2024-09-30 | Annual 2024 2024-06-30 | Q1 2024 2024-03-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-16.60M | $-5.79M | $-22.49M | $-16.94M |
Net Income | $-9.55M | $-5.06M | $-21.75M | $-17.03M |
EPS (Diluted) | $-0.45 | $-0.18 | $-1.22 | $-1.11 |
Total Assets | $79.07M | $68.77M | $52.21M | $15.00M |
Total Liabilities | $3.13M | $4.59M | $4.96M | $3.50M |
Cash & Equivalents | $78.28M | $67.84M | $50.87M | $14.10M |
Free Cash Flow OCF − CapEx | $-12.30M | Not available | $-19.58M | $-16.29M |
Shares Outstanding | 23.45M | 17.89M | 10.09M | 2.72M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.